FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh
FORT MILL, SC / ACCESSWIRE / September 11, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company in the growing field of cardiac electrophysiology, announced its first purchase order from the pacific northwest territory.As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT.The newest purchase order comes from the MultiCare Health System. The MultiCare Health System includes of 300 specialty care locations and twelve hospitals throughout Washington State, Idaho and Oregon."We continue to see continued growth from new hospitals and new territories throughout the US
FORT MILL, SC / ACCESSWIRE / September 5, 2024 / Catheter Precision, Inc. (NYSE:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of origin of ventricular tachycardia (VT) for patients with scar related re-entrant VT were presented. Additionally, the presentation showed the relationship to the relevant myocardial scar on cross-sectional imaging from the CT scan. The study, ongoing at the Warwick Medical School at the University Hospitals of Coventry and Warwickshire is ongoing with lead investigator Professor Tarv Dhanjal. The presentation was entitled "Accuracy of a non-invasiv
FORT MILL, SC / ACCESSWIRE / September 4, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, announced its first purchase order from a hospital in the greater Chicago area.As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the Chicago region.The newest purchase order comes from one of the hospitals within the the Endeavor Health System, which includes 9 hospitals, more than 300 care sites and over 7,100 physicians, making it the third largest healthcare system in Illinois."Since joining Catheter Pre
FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,623 common stock units issued upon exercise of the underwriters' over-allotment option, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit. Each common stock unit and pre-funded warrant unit consists of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001),
FORT MILL, SC / ACCESSWIRE / August 30, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company, today announced the pricing of its underwritten public offering of common stock units and pre-funded units for aggregate gross proceeds of approximately $3.1 million prior to deducting underwriting discounts and commissions and offering expenses.The equity offering is comprised of 347,277 common stock units, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit. Each common stock unit and pre-funded warrant unit consists of one share of common stock (or, in lieu of comm
FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report.Operational highlights include the following:First commercial sales of LockeT in the US14 new sales and clinical hires at various stages of training completionLarger number of US hospitals than projected have confirmed product interest and have scheduled evaluations23 hospitals for LockeT10 hospitals for VIVOVIVO product evaluation started at large volume center in ItalyNew LockeT publication in the Journal of Cardiovascular Electrop
FORT MILL, SC / ACCESSWIRE / August 6, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today the publication of its first LockeT study in the Journal of Cardiovascular Electrophysiology. The study titled, Feasibility, safety and efficacy of a novel external compression vascular closure device: The LockeT Study, was made available online on August 5, 2024.The study demonstrates the first clinical use of LockeT in 102 patients utilizing 182 LockeT devices and suggests that LockeT is effective for hemostasis, and early ambulation can be achieved with no major complications. The use of LockeT appears to generate the same benefits as standard o
FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today that it has enrolled 75 patients in its Phase II LockeT Study, which is now expected to conclude in October 2024.As previously disclosed, the three phases of the LockeT studies began in 2023 and are intended to show the product's safety and benefits. Phase I was completed in 2023 and showed that LockeT works for its intended purpose and that there were no safety events. Product roll-out began in the first half of 2024, while the Company continues Phase II of the product studies.Phase II compares manual compression, the current standard of care, to L
FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.As previously disclosed, the EU registry enrolled 125 patients with an aim to gather real world data about the use and benefits of VIVO, outside of a rigorous clinical study. The data serves multiple purposes including fulfilling European regulatory requirements for on-going data collection, publication of multi-center data, and future development of studies and improvements to the VIVO te
FORT MILLS, SC / ACCESSWIRE / July 15, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on July 15, 2024. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X 609.Pursuant to the reverse stock split, every 10 shares of the Company's issued common stock will be converted automatical
8-K - Catheter Precision, Inc. (0001716621) (Filer)
424B1 - Catheter Precision, Inc. (0001716621) (Filer)
S-1MEF - Catheter Precision, Inc. (0001716621) (Filer)
EFFECT - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
S-1/A - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
10-Q - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
SC 13G - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D - Catheter Precision, Inc. (0001716621) (Subject)
3 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
3 - Catheter Precision, Inc. (0001716621) (Issuer)
FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023.Highlights of the third quarter include the following: Received approval for first purchase in France. VIVO is now active in six European countries. Completed enrollment of Phase I LockeT study in excess of 100 patients. Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT. Finalized n
FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023.Highlights of the second quarter include the following:US sales team was assembled, trained, and is creating a pipeline.Additional US clinical personnel were onboarded and trained.Completion of enrollment of 125 patient VIVO patient Registry. Follow-up data is expected to be completed in June 2024.Key VIVO accounts continue to be established in both the US and Europe.Initiation of first L
Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.As previously disclosed, the EU registry enrolled 125 patients with an aim to gather real world data about the use and benefits of VIVO, outside of a rigorous clinical study. The data serves multiple purposes including fulfilling European regulatory requirements for on-going data collection, publication of multi-center data, and future development of studies and improvements to the VIVO technology, including a demonstration of the ac
U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 150 points on Monday. The Dow traded up 0.44% to 40,178.06 while the NASDAQ rose 0.29% to 18,451.73. The S&P 500 also rose, gaining, 0.25% to 5,629.59. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 2% on Monday. In trading on Monday, utilities shares fell by 1.8%. Top Headline Goldman Sachs Group Inc. (NYSE:GS) reported better-than-expected results for its second quarter. Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion.
Shares of SolarEdge Technologies, Inc. (NASDAQ:SEDG) fell sharply during Monday's session after the company announced a workforce reduction. SolarEdge disclosed a decision to lay off 400 employees. The company stated that 200 of these job cuts are in Israel. The action involves reducing headcount and discretionary spending across all departments. SolarEdge Technologies shares dipped 12.2% to $27.77 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Autonomix Medical, Inc. (NASDAQ:AMIX) shares climbed 148% to $1.4850 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Gener
U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday. The Dow traded up 0.73% to 40,291.69 while the NASDAQ rose 1.16% to 18,611.47. The S&P 500 also rose, gaining, 0.81% to 5,660.67. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 1.6% on Monday. In trading on Monday, utilities shares fell by 2.1%. Top Headline The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6. Equities Trading UP Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) sh
Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on July 15, 2024. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X 609.
Gainers Longeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million. JanOne (NASDAQ:JAN) stock rose 26.07% to $3.24. The company's market cap stands at $37.8 million. Bionomics (NASDAQ:BNOX) shares increased by 21.62% to $0.85. The market value of their outstanding shares is at $9.0 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 20.74% to $1.63. The company's market cap stands at $11.0 million. Holdco Nuvo Group DG (NASDAQ:NUVO) stock rose 20.22% to $1.84. The company's market cap stands at $61.2 million. Vivani Medical (NASDAQ:VANI) stock rose 15.9% to $1.89. The market value of their outstandin